Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-RAGE Subcutaneous Injection in Healthy Subjects
NCT05533294Phase 1Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Feb 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing ARO-RAGE with Placebo (2 arms). Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events up to 113 days. Started Nov 2022; status: completed.
02
Drugs
ARO-RAGE
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05533294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05533294.